The BARD/Veh group exhibited a significant increase in NF-κB p50 activation in the kidneys compared to the Veh/Veh (p = 0.01) and BARD/CIS (p = 0.02) groups (Fig. S3B). The gene discussed is NFKB1; the disease is in situ carcinoma.